Sai Life Sciences is a pure-play contract science partner that takes a new drug molecule from a chemist’s idea all the way to the factory floor - and it does nothing else. Founded in 1999 as a medicinal chemistry helper for American biotechs, it has spent two decades layering on biology labs, process-development centres and heavily regulated manufacturing plants until it became one of the few Indian companies that can genuinely claim to be an integrated CRDMO (contract research, development and manufacturing organization) for small-molecule drugs. The recurring logic is a science-led rather than capacity-led approach: the company adds laboratories, reactors and new technologies only when it already sees clear demand from the 300-plus innovator pharma and biotech firms it serves, which keeps its bets tightly coupled to what its customers are actually trying to make.
Business segments
Two deeply interlocked engines that together form a single small-molecule CRDMO platform - a discovery-services business that designs and tests new drug candidates, and a development-and-manufacturing business that scales them up for clinical trials and commercial supply.
1. Integrated Discovery Services: the front-end engine that turns biology into drug candidates
A globally distributed scientific workforce of over 2,000 R&D staff runs more than 200 discovery programs at any time, earning fees for the intellectual labour of designing, synthesising and testing molecules - not for selling the drugs themselves.
- Paid for scientific capacity, not product sales - revenue comes from Full-Time Equivalent (FTE) contracts, where dedicated teams of chemists and biologists are deployed to a customer’s project, and Fee-for-Service (FFS) contracts with defined scopes, so the company gets paid for the research work regardless of whether a molecule eventually becomes a drug.
- Biology is the new front door - the discovery engine combines medicinal chemistry with in-vitro biology, human cell-based assays and organoids (miniature lab-grown organs for testing), which matters because regulators like the USFDA are pushing the industry toward these New Approach Methodologies, creating demand for exactly the biology-heavy services the company has been building.
- Labs sit where the scientists are - discovery R&D is split across a 12-acre Hyderabad campus with 199 chemistry labs and pilot plants, a process-chemistry centre in Manchester, UK, and an exploratory biology lab embedded in the Cambridge-Boston life-sciences cluster, giving customers local access in two of the world’s biggest innovation hubs while the bulk of the work scales up cost-effectively in India.
- One roof from target to IND - the platform stitches together medicinal chemistry, DMPK (drug metabolism and pharmacokinetics - how a drug is absorbed and cleared), toxicology and formulation science, so a customer can take a biological target and arrive at an IND-ready candidate (a molecule cleared to enter human trials) without ever switching vendors.
- A dedicated customer fortress inside the campus - a 90-person R&D facility operated exclusively for a single global pharma innovator sits within the Hyderabad site, and the company is now replicating that dedicated-team model for other large-pharma clients on longer-duration programs, which locks in multi-year revenue streams.
2. Development & Manufacturing Services: the back-end engine that scales molecules into commercial drugs
Thirty-four commercial molecules and roughly 155 earlier-stage programs flow through a 700-kilolitre reactor network in Karnataka that has been inspected and cleared by both the USFDA and Japan’s PMDA - this is where the platform converts scientific work into long-term supply contracts.
- The reactor fleet is the factory floor - the Bidar campus houses 12 production blocks with 80 production trains and reactor sizes from 0.25 to 12 kilolitres, including high-containment HPAPI blocks for oncology drugs (containment below 0.1 µg/m³), clean rooms, lyophilisation (freeze-drying) and high-pressure capabilities, which together let the company handle everything from early clinical batches to commercial volumes for the most tightly regulated markets.
- Process chemistry bridges the gap - the Manchester Centre of Excellence and the Hyderabad CMC (Chemistry, Manufacturing and Controls) teams translate a lab-scale recipe into a factory-ready process using biocatalysis, flow chemistry and continuous extraction, which is how five molecules have travelled all the way from the company’s own discovery labs to commercial launch.
- Capacity is added in step with demand, not ahead of it - the newest production block, PB-11, reached its full ~200-kilolitre capacity in two phases during FY25-26, and a peptide pilot facility is targeted for September 2026, reflecting the philosophy of expanding only when customer molecules are visibly moving through the pipeline.
- Master Service Agreements create a steady funnel - eight large pharma companies have signed these umbrella agreements, which channel a continuous stream of early-phase molecules into the development portfolio and, over time, convert them into the 34 commercial products the company currently supplies, including seven blockbuster drugs with over US$1 billion in annual sales.
New modalities and technology capabilities
A cross-cutting capability layer that extends the small-molecule platform into peptides, antibody-drug conjugates, oligonucleotide building blocks and AI-enabled science - strengthening both discovery and manufacturing rather than sitting alongside them.
- Peptides are moving from lab to factory - a dedicated Peptide Research Center opened in Hyderabad in April 2025 with automation and robotics integrated into the discovery workflow, and a process-development and pilot facility is being built for commissioning by September 2026, with the near-term focus on supplying peptide fragments commercially.
- ADC work starts at the conjugation step - the company is building OEB (Occupational Exposure Band) laboratories for process development and upgrading to class-6 containment, having already completed bioconjugation at the discovery stage for a large pharma client, while evaluating whether to add clinical conjugation and fill-finish.
- Oligonucleotides mean amidites, not the full chain - the company focuses exclusively on making the amidite building blocks that go into oligonucleotide drugs, with multiple pharma projects spanning development to commercial stages, and a dedicated amidites block has been operating at Bidar since 2022.
- AI is being woven into the scientific workflow - the company has deployed AI-enabled retrosynthesis tools, built a High-Throughput Experimentation platform, and is developing AI-designed macrocyclic peptides, while digitising R&D and manufacturing processes to roughly 85% with a target of full manufacturing digitisation by calendar 2027.
Group structure and partners
A single listed Indian parent with three wholly-owned subsidiaries and a physical footprint spanning India, the US, the UK and Germany, stitched together by strategic partnerships that fill capability gaps without requiring the company to build everything itself.
- The listed entity is the operating company - Sai Life Sciences Limited, listed on the NSE and BSE since December 2024, directly owns subsidiaries in the US, India and Germany, with no complex holding-company layering.
- Six operating sites across four countries - the Hyderabad R&D campus (Unit II), the Bidar API manufacturing complex (Units IV and VI), a smaller intermediate plant at Bollaram (Unit III), a process-chemistry centre in Manchester, and a discovery lab in Greater Boston, with an additional 1.21-acre R&D site leased in Shamirpet, Hyderabad, in January 2025 to expand beyond the existing campus.
- Partnerships supply what the company does not own - a long-standing collaboration with Schrödinger provides computational drug-discovery tools; an Integrated CMC Partnership with Agility Life Sciences and Centrix Pharma Solutions, launched in October 2025, adds formulation and drug-product development so customers get a combined API-plus-formulation package; and a January 2026 deal with Mabtech turns the Boston lab into a co-marketed hub for advanced immunology assays.
- Industry memberships signal compliance credibility - the company is the first India-headquartered CRDMO to join the Pharmaceutical Supply Chain Initiative, is a signatory of the UN Global Compact, and sits on the ACS Green Chemistry Institute Pharmaceutical Roundtable, all of which matter to global pharma procurement teams evaluating supplier sustainability and ethics.